Free Trial

Karyopharm Therapeutics (KPTI) News Today

→ Don’t make this retirement mistake (From Sasco Gold LLC) (Ad)
Free KPTI Stock Alerts
$0.97
+0.01 (+1.05%)
(As of 06/10/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends
June 10 at 4:48 AM | americanbankingnews.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Sells $449,322.24 in Stock
June 9 at 5:30 AM | insidertrades.com
Deepika Pakianathan Sells 231,548 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock
June 9 at 3:24 AM | americanbankingnews.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of "Moderate Buy" by Analysts
June 7 at 10:26 PM | marketbeat.com
Insider Selling: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Sells 231,548 Shares of Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) Director Deepika Pakianathan sold 231,548 shares of the stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $0.95, for a total value of $219,970.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
June 6, 2024 | insidertrades.com
Insider Selling: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Sells 204,394 Shares of Stock
June 5, 2024 | americanbankingnews.com
Brokers Issue Forecasts for Karyopharm Therapeutics Inc.'s FY2025 Earnings (NASDAQ:KPTI)
June 5, 2024 | marketbeat.com
Leerink Partnrs Analysts Reduce Earnings Estimates for Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a report issued on Sunday, June 2nd. Leerink Partnrs analyst J. Chang now expects that the company w
June 5, 2024 | americanbankingnews.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Director Deepika Pakianathan Sells 360,744 Shares
June 4, 2024 | marketbeat.com
Deepika Pakianathan Sells 204,394 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) Director Deepika Pakianathan sold 204,394 shares of the business's stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $0.95, for a total value of $194,174.30. Following the sale, the director now owns 14,697 shares in the company, valued at $13,962.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
June 3, 2024 | prnewswire.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 3, 2024 | americanbankingnews.com
Karyopharm Therapeutics (NASDAQ:KPTI) Given "Buy" Rating at HC Wainwright
June 1, 2024 | prnewswire.com
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
May 29, 2024 | prnewswire.com
Karyopharm to Participate at the Jefferies Global Healthcare Conference
May 23, 2024 | investorplace.com
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
May 15, 2024 | marketbeat.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Analysts
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and three have issued a buy ratin
May 10, 2024 | seekingalpha.com
KPTI Karyopharm Therapeutics Inc.
May 10, 2024 | markets.businessinsider.com
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
May 10, 2024 | finance.yahoo.com
Karyopharm Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 9, 2024 | markets.businessinsider.com
Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials
May 9, 2024 | finance.yahoo.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript
May 9, 2024 | marketbeat.com
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $8.00 price target on shares of Karyopharm Therapeutics in a report on Thursday.
May 9, 2024 | finance.yahoo.com
Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
May 8, 2024 | finance.yahoo.com
Q1 2024 Karyopharm Therapeutics Inc Earnings Call
May 8, 2024 | finanznachrichten.de
Karyopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 8, 2024 | finance.yahoo.com
Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review
May 8, 2024 | markets.businessinsider.com
Karyopharm Therapeutics Inc. Q1 Loss increases, but beats estimates
May 8, 2024 | prnewswire.com
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
May 8, 2024 | investorplace.com
KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 8, 2024 | prnewswire.com
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 8, 2024 | prnewswire.com
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
May 3, 2024 | marketbeat.com
Karyopharm Therapeutics (KPTI) Scheduled to Post Earnings on Wednesday
Karyopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.
May 2, 2024 | prnewswire.com
Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024
May 1, 2024 | prnewswire.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2024 | prnewswire.com
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
April 1, 2024 | prnewswire.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 15, 2024 | finance.yahoo.com
KPTI Apr 2024 5.000 call
March 15, 2024 | finance.yahoo.com
KPTI Apr 2024 1.500 put
March 14, 2024 | businesswire.com
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO ® (selinexor)
March 6, 2024 | finance.yahoo.com
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
March 5, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
March 5, 2024 | finance.yahoo.com
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
March 2, 2024 | seekingalpha.com
Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript
March 1, 2024 | prnewswire.com
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 1, 2024 | marketbeat.com
Karyopharm Therapeutics (NASDAQ:KPTI) Releases Quarterly Earnings Results, Misses Expectations By $0.07 EPS
Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The company had revenue of $33.75 million during the quarter, compared to analyst estimates of $33.50 million. During the same period in the prior year, the company earned ($0.43) earnings per share.
March 1, 2024 | finance.yahoo.com
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
March 1, 2024 | marketbeat.com
Brokers Offer Predictions for Karyopharm Therapeutics Inc.'s FY2025 Earnings (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at Leerink Partnrs issued their FY2025 earnings per share estimates for Karyopharm Therapeutics in a research note issued to investors on Thursday, February 29th. Leerink Partnrs analyst J. Chang expects that the company wi
March 1, 2024 | marketbeat.com
Karyopharm Therapeutics (NASDAQ:KPTI) PT Lowered to $8.00 at HC Wainwright
HC Wainwright decreased their price objective on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research report on Friday.
February 29, 2024 | fool.com
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
February 29, 2024 | finance.yahoo.com
Q4 2023 Karyopharm Therapeutics Inc Earnings Call
February 29, 2024 | finanznachrichten.de
Karyopharm Therapeutics Inc.: Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.

DON’T buy gold until you read this (Ad)

If you're an American who understands that your money is rotting away as you read this email… Then this is for YOU. 99% of people are buying gold the wrong way.

Reserve your seat here.

KPTI Media Mentions By Week

KPTI Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

KPTI
News Sentiment
▼
-0.10

0.76
▲
Average
Medical
News Sentiment

KPTI News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

KPTI Articles
This Week
▼
18

2
▲
KPTI Articles
Average Week

Get Karyopharm Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:KPTI) was last updated on 6/10/2024 by MarketBeat.com Staff

From Our Partners
Bill Clinton Backing Biden Replacement???
Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...
The Freeport Society | Sponsored
DON’T buy gold until you read this
If you're an American who understands that your money is rotting away as you read this email… Then this is ...
Sasco Gold LLC | Sponsored
Shocking $16T Elon Musk Crypto Leak
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...
Crypto 101 Media | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Hurry! Buy this stock before the Robinhood traders do!
Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...
Traders Agency | Sponsored
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...
Wealthpin Pro | Sponsored